142 related articles for article (PubMed ID: 10334524)
1. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Costanza ME; Weiss RB; Henderson IC; Norton L; Berry DA; Cirrincione C; Winer E; Wood WC; Frei E; McIntyre OR; Schilsky RL
J Clin Oncol; 1999 May; 17(5):1397-406. PubMed ID: 10334524
[TBL] [Abstract][Full Text] [Related]
2. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
[TBL] [Abstract][Full Text] [Related]
5. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
7. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
Vogel CL; Smalley RV; Raney M; Krauss S; Carpenter J; Velez-Garcia E; Fishkin E; Raab S; Moore MR; Stagg M
J Clin Oncol; 1984 Jun; 2(6):643-51. PubMed ID: 6374057
[TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Jassem J; Pieńkowski T; Płuzańska A; Jelic S; Gorbunova V; Mrsic-Krmpotic Z; Berzins J; Nagykalnai T; Wigler N; Renard J; Munier S; Weil C;
J Clin Oncol; 2001 Mar; 19(6):1707-15. PubMed ID: 11251000
[TBL] [Abstract][Full Text] [Related]
11. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
[TBL] [Abstract][Full Text] [Related]
12. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T; Nomizu T; Toi M; Ito Y; Noguchi S; Kobayashi T; Asaga T; Minami H; Yamamoto N; Aogi K; Ikeda T; Ohashi Y; Sato W; Tsuruo T
J Clin Oncol; 2007 Feb; 25(4):411-7. PubMed ID: 17179098
[TBL] [Abstract][Full Text] [Related]
13. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
Falkson G; Holcroft C; Gelman RS; Tormey DC; Wolter JM; Cummings FJ
J Clin Oncol; 1995 Jun; 13(6):1453-8. PubMed ID: 7751892
[TBL] [Abstract][Full Text] [Related]
14. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
15. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
16. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
Perry MC; Kardinal CG; Korzun AH; Ginsberg SJ; Raich PC; Holland JF; Ellison RR; Kopel S; Schilling A; Aisner J
J Clin Oncol; 1987 Oct; 5(10):1534-45. PubMed ID: 3655856
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) Study, Italy.
Baldini E; Gardin G; Giannessi P; Brema F; Camorriano A; Carnino F; Naso C; Pastorino G; Pronzato P; Rosso R; Rubagotti A; Torretta G; Conte PF
Tumori; 1997; 83(5):829-33. PubMed ID: 9428917
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
Stewart DJ; Evans WK; Shepherd FA; Wilson KS; Pritchard KI; Trudeau ME; Wilson JJ; Martz K
J Clin Oncol; 1997 May; 15(5):1897-905. PubMed ID: 9164200
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
